Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: Outcome after resumption of therapy-Reference-Cited by-同舟云学术

Acute sensorineural hearing loss associated with peginterferon and ribavirin combination therapy during hepatitis C treatment: Outcome after resumption of therapy

Published:2005 Issue:34 Volume:11 Page:5392
ISSN:1007-9327
Container-title:World Journal of Gastroenterology
language:en
Short-container-title:WJG

Author:

Wong Victor K

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,General Medicine

Reference14 articles.

1. Patrick DM, Buxton JA, Bigham M, Mathias RG. Public health and hepatitis C. Can J Public Health 2000;91 Suppl 1:S18-21, S19-23.

2. Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C

3. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

4. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

5. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Audiovestibular and vaccination complications of COVID-19;The Egyptian Journal of Otolaryngology;2022-08-19

2. A Narrative Review of Pharmacologic Treatments for COVID ‐19: Safety Considerations and Ototoxicity;The Laryngoscope;2021-01-27

3. Visual and brainstem auditory evoked potentials in HCV-infected patients before and after interferon-free therapy — A pilot study;International Journal of Infectious Diseases;2019-03

4. Cochlear Changes Caused by Peginterferon α-2b;Journal of Interferon & Cytokine Research;2018-07

5. Retinopathy and Uveitis Associated with Sofosbuvir Therapy for Chronic Hepatitis C Infection;Cureus;2016-05-03